Literature DB >> 9075297

Attentional vulnerability indicators in schizophrenia and bipolar disorder.

J Addington1, D Addington.   

Abstract

Visual attention and positive and negative symptoms were assessed in 59 inpatients with a relapse of schizophrenia and 3 months later during a period of relative remission. Visual attention was measured with the Continuous Performance Task (CPT) and the Span of Apprehension Task (SPAN). At follow-up schizophrenia subjects were compared on visual attention to 40 outpatients with bipolar disorder and 40 normal controls. Although symptoms improved significantly, the schizophrenia subjects' performance on the CPT and SPAN was relatively stable over time. Poor visual attention was significantly associated with high levels of negative, but not positive symptoms at the 3-month follow-up. The schizophrenia subjects had poorer visual attention than the normal controls. There were no differences between the schizophrenia and the bipolar subjects. These results offer partial support to the hypothesis that deficits in visual attention may be negative symptom-linked vulnerability indicators.

Entities:  

Mesh:

Year:  1997        PMID: 9075297     DOI: 10.1016/s0920-9964(96)00105-3

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  16 in total

1.  Deficits in frontoparietal activation and anterior insula functional connectivity during regulation of cognitive-affective interference in bipolar disorder.

Authors:  Kristen K Ellard; Aishwarya K Gosai; Julia M Felicione; Amy T Peters; Conor V Shea; Louisa G Sylvia; Andrew A Nierenberg; Alik S Widge; Darin D Dougherty; Thilo Deckersbach
Journal:  Bipolar Disord       Date:  2018-11-22       Impact factor: 6.744

2.  Distractibility and symptoms in schizophrenia.

Authors:  J Addington; D Addington; L Gasbarre
Journal:  J Psychiatry Neurosci       Date:  1997-05       Impact factor: 6.186

3.  Functional dysconnectivity in schizophrenia associated with attentional modulation of motor function.

Authors:  Garry D Honey; Edith Pomarol-Clotet; Philip R Corlett; Rebekah A E Honey; Peter J McKenna; Edward T Bullmore; Paul C Fletcher
Journal:  Brain       Date:  2005-09-23       Impact factor: 13.501

4.  Effortful cognitive resource allocation and negative symptom severity in chronic schizophrenia.

Authors:  Eric Granholm; Steven P Verney; Dimitri Perivoliotis; Tamie Miura
Journal:  Schizophr Bull       Date:  2006-09-06       Impact factor: 9.306

5.  A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state.

Authors:  Matthew M Kurtz; Raphael T Gerraty
Journal:  Neuropsychology       Date:  2009-09       Impact factor: 3.295

Review 6.  Disorders of thought are severe mood disorders: the selective attention defect in mania challenges the Kraepelinian dichotomy a review.

Authors:  C Raymond Lake
Journal:  Schizophr Bull       Date:  2007-05-21       Impact factor: 9.306

Review 7.  Should cognitive deficit be a diagnostic criterion for schizophrenia?

Authors:  Ralph Lewis
Journal:  J Psychiatry Neurosci       Date:  2004-03       Impact factor: 6.186

Review 8.  Sustained attention in psychosis: Neuroimaging findings.

Authors:  Gianna Sepede; Maria Chiara Spano; Marco Lorusso; Domenico De Berardis; Rosa Maria Salerno; Massimo Di Giannantonio; Francesco Gambi
Journal:  World J Radiol       Date:  2014-06-28

9.  Shared neurocognitive dysfunctions in young offspring at extreme risk for schizophrenia or bipolar disorder in eastern quebec multigenerational families.

Authors:  Michel Maziade; Nancie Rouleau; Nathalie Gingras; Pierrette Boutin; Marie-Eve Paradis; Valérie Jomphe; Julie Boutin; Karine Létourneau; Elsa Gilbert; Andrée-Anne Lefebvre; Marie-Claire Doré; Cecilia Marino; Marco Battaglia; Chantal Mérette; Marc-André Roy
Journal:  Schizophr Bull       Date:  2008-06-11       Impact factor: 9.306

Review 10.  Markers of vulnerability in schizophrenia.

Authors:  Maria Ladea; Dan Prelipceanu
Journal:  J Med Life       Date:  2009 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.